An observational study in Presbyopia, sponsored by Vance Thompson Vision. Completed at 1 site in United States. Open to participants aged 37 Years to 48 Years. Per ClinicalTrials.gov, last updated 2021-03-30.
Sponsored by Vance Thompson Vision · Observational
Educating patients on visual performance with presbyopic correcting intraocular lenses is crucial. Understanding the defocus curve of pre-presbyopic and emerging presbyopic crystalline lens will provide eye care provides useful information to better educate patients on visual performance expectations after cataract surgery with a presbyopic correcting intraocular lens. Our objective will be to assess the subjective range of clear vision of a pre-presbyopic and emerging presbyopic patient population utilizing a defocus curve. A comparison of the pre-presbyopic and emerging presbyopic defocus curve to all FDA-approved presbyopic intraocular lenses will be discussed in the manuscript.
324 studies on the registry are indexed under Presbyopia; 33 are open to participants now.
This study's enrollment of 45 is below the median of 80 across 51 observational studies indexed under Presbyopia.
Browse Presbyopia studies →Vance Thompson Vision is the lead sponsor of 20 studies on the registry; 7 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
A population of 30-60 subjects will be selected for testing. Subjects can be male or female, ages 37-48.
Exclusion Criteria:
There is not an intervention
Change in LogMar visual acuity during vision testing on ETDRS with loose lenses
Time frame: Screening/enrollment visit
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vance Thompson Vision